This study from Wakely, an HMA Company, created for the Pharmaceutical Care Management Association (PCMA), analyzes what happens when a small‑molecule brand drug loses patent protection—how quickly generics capture market share and how much prices fall at the pharmacy counter. Using national claims data, we compare “Major” versus “Other” launches (based on pre‑launch brand spend) and evaluate outcomes in the first six months after launch (the exclusivity phase) and the period that follows.
